UK plans 30% funding bump for translational research von Perks, Bea

Volltext

New regulations urged for UK health research von Perks, Bea

Volltext

Ariad patent decision points to description dilemma von Perks, Bea

Volltext

Pharma's Asian syndicate von Perks, Bea

Volltext

International Alliance of Patients’ Organizations toolkit for biological and biosimilar medicines von Perks, Bea

Volltext

Pharmaceutical policy interventions in times of economic recession von Perks, Bea

Volltext

Weighing up the cost of switching to biosimilars von Perks, Bea

Volltext

Drug shortages hit US oncologists hard von Perks, Bea

Volltext

Biosimilarity of anticancer monoclonal antibodies in the clinic von Perks, Bea

Volltext

Randomized non-inferiority trial fails to find inferiority switching from infliximab originator to CT-P13 biosimilar von Perks, Bea

Volltext

Biosimilar monoclonal antibodies – time for a regulatory rethink von Perks, Bea

Volltext

Careers in Chemistry: Constantly Evolving Choices von Perks, Bea

Volltext

Supporting biosimilarity and extrapolation von Perks, Bea

Volltext

Suppressing the suppressors von Perks, Bea

Volltext

Therapeutic potential of a communication breakdown von Perks, Bea

Volltext

Careers in Chemistry: Constantly Evolving Choices von Perks, Bea

Volltext

FP6 brings bigger funds and some confusion von Perks, Bea

Volltext

A role for the proteasome in HIV infection von Perks, Bea

Volltext

SDF-1: the repulsive chemokine von Perks, Bea

Volltext

T-cell costimulation in a new LIGHT von Perks, Bea

Volltext